CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 28 enrolled
Drug / intervention
Tremelimumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02563925
NCT02563925N/ACompleted
CompareCT.gov

A Pilot Study of Brain Irradiation and Tremelimumab in Metastatic Breast Cancer

Memorial Sloan Kettering Cancer Center·interventional·Posted Sep 30, 2015·Updated Aug 3, 2022

In Brief

A clinical study evaluating Brain radiotherapy or Stereotactic Radiosurgery, Tremelimumab, and 2 other interventions for Metastatic Breast Cancer. Completed, enrolled 28 participants across 1 site.

Detailed Summary

The purpose of this study is to see if the combination of tremelimumab and durvalumab with brain radiation therapy can help treat this type of breast cancer that has spread to the brain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesUnited States
CollaboratorsMedImmune LLC

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 30, 2015
Enrollment StartSep 18, 2015
Primary CompletionJul 14, 2021
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 10.8 years ago

Interventions

Brain radiotherapy or Stereotactic Radiosurgeryradiation

Tremelimumabdrug

HER2 directed therapydrug

Durvalumabdrug